These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2454363)

  • 21. Beta-blockers in heart failure: potential of carvedilol.
    Fowler MB
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S62-7. PubMed ID: 8098065
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Alpha beta-blockers for patients with hypertension].
    Mizuta Y; Imaizumi T
    Nihon Rinsho; 2006 Aug; 64 Suppl 6():305-9. PubMed ID: 16981560
    [No Abstract]   [Full Text] [Related]  

  • 23. Do hybrid drugs offer an additional benefit over pure alpha 1-blockade for hypertensive patients?
    Doyle AE
    J Hypertens Suppl; 1988 Dec; 6(2):S51-3. PubMed ID: 2906701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking.
    Vyssoulis GP; Marinakis AG; Aznaouridis KA; Karpanou EA; Arapogianni AN; Cokkinos DV; Stefanadis CI
    Am J Hypertens; 2004 Jul; 17(7):582-9. PubMed ID: 15233977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical and clinical pharmacology of carvedilol.
    Ruffolo RR; Boyle DA; Venuti RP; Lukas MA
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S2-15. PubMed ID: 8487245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resting and postexercise hemodynamic effects of carvedilol, a beta-adrenergic blocker and precapillary vasodilator in hypertensive patients.
    Leonetti G; Sampieri L; Cuspidi C; Boselli L; Terzoli L; Rupoli L; Zanchetti A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S94-6. PubMed ID: 2454377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients.
    Eggertsen R; Sivertsson R; Andrén L; Hansson L
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S97-100. PubMed ID: 2454378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antihypertensive effect of labetalol, a new alpha- and beta-adrenergic blocking agent.
    Hansson L; Hänel B
    Int J Clin Pharmacol Biopharm; 1976 Oct; 14(3):195-8. PubMed ID: 12115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term hemodynamic effects at rest and during exercise of newer antihypertensive agents and salt restriction in essential hypertension: review of epanolol, doxazosin, amlodipine, felodipine, diltiazem, lisinopril, dilevalol, carvedilol, and ketanserin.
    Omvik P; Lund-Johansen P
    Cardiovasc Drugs Ther; 1993 Apr; 7(2):193-206. PubMed ID: 8395198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of labetalol with other anti-hypertensive drugs.
    Prichard BN; Richards DA
    Br J Clin Pharmacol; 1982 Jun; 13(1 Suppl):41S-47S. PubMed ID: 6124265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological and clinical aspects of drug therapy in coronary heart disease: clinical aspects of therapy with beta-adrenoceptor antagonists.
    Prichard BN
    Z Kardiol; 1990; 79 Suppl 3():99-103. PubMed ID: 1983055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of multiple action agents in hypertension.
    Lund-Johansen P; Omvik P
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S89-95. PubMed ID: 1974512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravenous labetalol in the emergency treatment of hypertension.
    Vidt DG
    J Clin Hypertens; 1985 Jun; 1(2):179-86. PubMed ID: 3915322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol.
    González Maqueda I
    Coron Artery Dis; 1994 Nov; 5(11):909-18. PubMed ID: 7719523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Betablockers in the treatment of hypertension (with special emphasis on betablockers with ISA). A review.
    Widimský J; Lefflerová K
    Cor Vasa; 1988; 30(5):368-75. PubMed ID: 2906581
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation of the risk for drug-induced postural hypotension in an experimental model: investigations with carvedilol, prazosin, labetalol, and guanethidine.
    Bartsch W; Sponer G; Strein K; Böhm E; Hooper RG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S49-51. PubMed ID: 2454367
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha- and beta-receptor blocking drugs in the treatment of hypertension.
    Ram CV; Kaplan NM
    Curr Probl Cardiol; 1979 Jan; 3(10):1-53. PubMed ID: 40755
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celiprolol in hypertension.
    Taylor SH
    Am Heart J; 1988 Nov; 116(5 Pt 2):1426-34. PubMed ID: 2903654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacologic and physiologic considerations of adrenoceptor blockade.
    Frohlich ED; Dunn FG; Messerli FH
    Am J Med; 1983 Oct; 75(4A):9-14. PubMed ID: 6139019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta-adrenoceptor blocking drugs and their use in hypertension.
    Prichard NC
    S Afr Med J; 1976 Nov; 50(47):1902-9. PubMed ID: 12577
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.